By Kelly Cloonan
Shares of Instil Bio climbed after the company shared progress on a trial in China for its non-small cell lung cancer treatment in combination with chemotherapy and said it is preparing to start U.S. clinical development for the drug.
The stock rose 54% to $24.99 on Thursday. Shares have more than doubled over the past 12 months.
The biopharmaceutical company on Thursday said it has enrolled more than 30 patients in its Phase 2 trial in China, and over 20 have been treated with the drug combination since the end of March.
The trial is now on track to complete enrollment of about 60 patients in the third quarter and report initial results in the second half of the year, Instil said.
The drug has an objective response rate of 23%, similar to competitor bispecific antibodies at a similar stage of development, the company said.
Instil also said it plans to initiate a trial of the drug in the U.S. before the end of 2025, pending regulatory approvals. The trial will test a monotherapy dose in relapsed or refractory solid tumors, aiming to accelerate the path to a potential global Phase 3 trial of the drug in first-line non-small-cell lung cancer, the company said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
May 22, 2025 12:45 ET (16:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.